Navigation Links
Progen Announces PI-88 Phase 2 Lung Cancer Results
Date:9/24/2007

BRISBANE, Sept. 24 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced that the Phase 2 trial administering 250mg of PI-88 in combination with the chemotherapeutic agent docetaxel to patients with advanced non small cell lung cancer did not meet its primary endpoint of significantly improving the progression-free rate at six months compared to docetaxel alone. The trial also did not meet its secondary endpoints of improvement in time to progression, response rate, overall survival and quality of life measures.

The overall data from this trial suggests that no further investigation of PI-88 in combination with docetaxel in patients with non small cell lung cancer that have failed platinum based first line therapies is warranted. However, nine patients in the study switched to PI-88 after experiencing toxicity or disease progression with docetaxel monotherapy. The data for this patient group suggests a potential survival benefit that Progen intends to investigate further with, amongst others, the clinicians involved in this study.

"We are disappointed, first and foremost, for the patients with non small cell lung cancer that have disease progression following platinum based chemotherapy as treatment options are limited," said Justus Homburg, Progen's Chief Executive Officer. "The outcome of this study has no impact on our Phase 3 registration strategy for patients with post-resection liver cancer which we announced today has been granted fast-track status designation by the U.S. FDA."

"It is quite common for new drugs to show benefit in one patient group but limited benefit in another. To date, PI-88 has shown evidence of benefit in patients with melanoma, multiple myeloma and post-resection liver cancer. In particular, PI-88 may be more active for tumors that are at an earlier disease stage, such as has been demonstrated in the PI-88 Phase 2 primary liver cancer trial" added Homburg. "In that trial, patients were at high risk of disease recurrence but had no demonstrable disease present at the time of starting therapy with PI-88" he said. "We remain committed to the ongoing development of PI-88, especially given the exciting Phase 2 data seen in the primary liver cancer trial."

About Progen:

Progen Pharmaceuticals Limited is an Australian-based globally focused biotechnology company committed to the discovery, development and commercialization of small molecule therapeutics primarily for the treatment of cancer.

Progen Information:

Justus Homburg

Progen Pharmaceuticals Limited

T: +61 7 3842 3333

E: justush@progen-pharma.com

Sarah Meibusch

Progen Pharmaceuticals Limited

T: +61 7 3842 3333

E: sarahm@progen-pharma.com

Media and Investor Relations Australia:

Rebecca Piercy

Buchan Consulting

T: +61 2 9237 2800 / +61 422 916 422

E: rpiercy@bcg.com.au

Rebecca Wilson

Buchan Consulting

T: +61 417 382 391

E: rwilson@bcg.com.au

Media Relations USA:

Robert D. Stanislaro

Financial Dynamics

T: 212-850-5657

E: robert.stanislaro@fd.com

Investor Relations USA:

Evan Smith

Financial Dynamics

T: 212-850-5606

E: evan.smith@fd.com


'/>"/>
SOURCE Progen Pharmaceuticals Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
3. Progens Phase 2 Liver Cancer Trial Exceeds Efficacy Objective
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... JERUSALEM , July 5, 2017 ... www.oramed.com ), a clinical-stage pharmaceutical company ... today that it has received approval from the Israel Securities ... Stock Exchange (TASE). Oramed common stock will commence trading on ... Based on the current market capitalization of the Company, it ...
(Date:7/1/2017)... 30, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... conference call will be broadcast live over the Internet on ... news release detailing the quarterly results will be made available ... call. The live audio webcast can be accessed ... It will be archived for replay following the conference call. ...
(Date:6/30/2017)... -- Axium Pharmaceuticals Inc. is a pharmaceutical company aimed at utilizing drug ... forms of existing biologically active molecule. ... Subveta oral spray ... formula, which is designed to prevent precipitation of the active ... provide fast onset of action and is designed to optimize ...
Breaking Medicine Technology:
(Date:7/20/2017)... SANTA CLARA, CA (PRWEB) , ... July 20, ... ... some form of travel protection services since 2014, top travel insurance solution company ... agents the tools to sell all major international travel insurance products online, under ...
(Date:7/20/2017)... , ... July 19, 2017 , ... At Creekwood Dental ... of temporomandibular joint (TMJ) treatment and dental implants in Waco, TX, using ... scanner and the T-Scan™ by Tekscan®, they can capture details in the oral cavity ...
(Date:7/20/2017)... ... 2017 , ... A July 7th article on ... veins in some patients, according to medical experts. Washington State medical clinic Northwest ... sitting or standing, or regularly nicking yourself while shaving your legs, and taking ...
(Date:7/18/2017)... ... July 18, 2017 , ... ClinicalTrials.gov and the New ... Need to Consider?, **An FDAnews Webinar**, Aug. 2, 2017 — 1:30 p.m. – ... Rule for Clinical Trials Registration and Results Information,” is a head-scratcher. After reading ...
(Date:7/18/2017)... ... ... Heritage Woods of Benton, a Gardant affordable assisted living community is hosting ... The community, which is located at 1305 Bailey Lane in Benton, Illinois, serves older ... their independence. , The lunch menu will include Hawaiian chicken, meatballs and coleslaw. Tropical ...
Breaking Medicine News(10 mins):